NCT00287248View on ClinicalTrials.gov

Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the Brain

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

February 29, 2008

Study Completion Date

March 31, 2008

Conditions
Alzheimer Disease
Interventions
DRUG

[123I] IMPY & SPECT Imaging

Subjects will be injected with 7mCi of \[123I\]IMPY, followed by SPECT imaging

Trial Locations (1)

06510

Institute for Neurodegenerative Disorders, New Haven

Sponsors

Collaborators (1)

Molecular NeuroImaging
All Listed Sponsors
collaborator

Alzheimer's Association

OTHER

collaborator

Molecular NeuroImaging

OTHER

lead

Institute for Neurodegenerative Disorders

OTHER